April 2, 2021

The Neutralization Potency of Anti-SARS-CoV-2 Therapeutic Human Monoclonal Antibodies Is Retained against Novel Viral Variants

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): treatment

• [Pre-print, not peer-reviewed] Neutralizing activity of four experimental monoclonal antibodies (mAbs) (MD65, MD62, MD29 and BL6) targeting the receptor-binding domain (RBD) of SARS-CoV-2 were largely retained against a panel of the top 10 RBD mutations including mutations found in several variants of concern.

Rosenfeld et al. (Apr 1, 2021). The Neutralization Potency of Anti-SARS-CoV-2 Therapeutic Human Monoclonal Antibodies Is Retained against Novel Viral Variants. Pre-print downloaded Apr 2 from https://doi.org/10.1101/2021.04.01.438035